IV care from different perspectives

22 July 2021
Volume 30 · Issue 14

This Supplement includes articles from the US-based Association for Vascular Access (AVA) and the Canadian Vascular Access Association (CVAA). Here are some observations on these articles from a UK point of view.

I was interested to read this AVA article. In this study, the effectiveness and safety of a catheter lock solution containing 2% taurolidine without citrate or heparin (TauroSept®, Geistlich Pharma AG, Wolhusen, Switzerland) in haemodialysis patients was investigated. The results were very promising with an observed catheter-related bloodstream infection rate of 0 per 1000 catheter days.

TauroSept is classed as a medical device in the UK and, in this case, a prescription is not required for its use. This has many advantages and, in my own clinical practice, I have seen great results in clearing candida from tunnelled catheters using TauroSept as a treatment and as a prophylactic lock.

An innovative strategy to upskill the student nursing body with cannulation and venepuncture competencies to aid in coping with the pressures of COVID-19 surges in an acute Canadian hospital is discussed in this article from the CVAA.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content